Deep Track Capital’s Keros Therapeutics KROS Stock Holding History

Deep Track Capital’s Portfolio KROS Stock Details KROS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-248,500	Closed	-$9.35M	–	67
2022 Q3	$9.35M	Sell	248,500 -491,028	-66%	-$17M	0.43%	51
2022 Q2	$20.4M	Sell	739,528 -640,778	-46%	-$28.1M	1.34%	26
2022 Q1	$75.1M	Buy	1,380,306 +80,306	+6%	+$4.12M	4.81%	10
2021 Q4	$76.1M	Buy	+1,300,000	New	+$64.8M	5.37%	1

Other funds holding KROS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Deep Track Capital's KROS Position: Q4 2022 in Review

Deep Track Capital sold out of Keros Therapeutics (KROS) in Q4 2022, closing a stake of 248,500 shares — an estimated $9.35M sold.

Deep Track Capital first reported a position in KROS in Q4 2021 and held it in 4 quarters. The position peaked at $76.1M in Q4 2021. 126 funds tracked by Wall St. Rank hold KROS as of Q4 2022.

Deep Track Capital reported no remaining Keros Therapeutics position as of Q4 2022 after selling out during the quarter.
Deep Track Capital sold 248,500 Keros Therapeutics shares in Q4 2022, an estimated $9.35M.
Deep Track Capital first reported a position in Keros Therapeutics in Q4 2021 and held it in 4 quarters.
Deep Track Capital's Keros Therapeutics position peaked at $76.1M in Q4 2021.
126 funds tracked by Wall St. Rank held Keros Therapeutics as of Q4 2022.

Based on Deep Track Capital's 13F filing for Q4 2022, filed 14 Feb 2023.